In a news released in October 2025, Candel Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced interim ...

Improving equitable access to genomics-based clinical trials remains a critical priority in cancer care, according to Dr.

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

Today, I live with cancer, but I don’t let it define me. I choose to define my story by courage, trust, and hope. I’ve ...

Reolysin and Tecentriq combination therapy achieved a 29% objective response rate in third-line metastatic squamous cell anal ...

Ernie Strauss and Ronald Wakefield, who met through the patient navigation program of Northside Hospital, have built a ...

Bill Potts, a five-time cancer survivor, stresses the importance of self-advocacy and owning one's cancer journey, including seeking multiple opinions. High-volume cancer centers are recommended for ...

In this segment, multiple myeloma care partners direct others to vital sources of hope and practical information.

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...

Oya Gilbert blends hip-hop and advocacy to raise awareness about myeloma, engage patients, and address broader health issues ...

Donna Rigby, a grandmother living in Asbury Park, New Jersey and a former licensed practical nurse (LPN), experienced a ...

Dr. Ian Flinn, chief scientific officer at Tennessee Oncology and One Oncology in Nashville, Tennessee, explains Lunsumio ...